Showing 4561-4570 of 5771 results for "".
- AstraZeneca Kicks Off Phase 3 Study of COVID-19 Vaccine AZD1222 in the UShttps://modernod.com/news/astrazeneca-kicks-off-phase-3-study-of-covid-19-vaccine-azd1222-in-the-us/2478229/AstraZeneca announced the start of a phase 3 study in the US investigating its experimental COVID-19 vaccine AZD1222 in up to 30,000 adults aged 18 years or over. Subjects in the trial, called D8110C00001, will be randomized to receive two doses of either AZD1222 or a saline control, 4 weeks apar
- Oculis Establishes Presence in US and Appoints Sylvia Cheung as Chief Financial Officerhttps://modernod.com/news/oculis-establishes-presence-in-us-and-appoints-sylvia-cheung-as-chief-financial-officer/2478231/Oculis established a US entity, Oculis Inc., and announced the appointment of Sylvia Cheung as Chief Financial Officer (CFO). Ms. Cheung will be based in the newly established Oculis US entity and succeeds Páll Ragnar Jóhannesson who becomes Oculis Chief Strategy Officer. “We are very plea
- Zeiss Launches Virtual Optometry Hubhttps://modernod.com/news/zeiss-launches-virtual-optometry-hub/2478226/Zeiss announced it is launching the Zeiss Virtual Optometry Hub on September 20-21. In the all-new 360° experience, visitors will be able to take a walk through the Zeiss Virtual Practice and see how diagnostic equipment and data management can integrate seamlessly to provide a sophisticated prac
- RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial in November 2020https://modernod.com/news/regenerx-joint-venture-expects-to-complete-phase-3-dry-eye-trial-in-november-2020/2478222/RegeneRx Biopharmaceuticals announced that its US joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. According to GtreeBNT, the ARISE-3 trial was delayed a few months due to COVID-19; h
- Health Canada Authorizes Enspryng for Canadians Living with Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/health-canada-authorizes-enspryng-for-canadians-living-with-neuromyelitis-optica-spectrum-disorder/2478219/Roche Canada announced that Health Canada has granted market authorization for Enspryng (satralizumab) as monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent patients who are anti-aqu
- Vision Expo to Host Virtual Career Zone Event on September 22https://modernod.com/news/vision-expo-to-host-virtual-career-zone-event-on-september-22/2478215/Vision Expo announced plans to host the Virtual Career Zone, a virtual networking event designed to connect young professionals and students with prominent optical companies. Set to take place on Tuesday, September 22 from 11-11:55 a.m. EDT, the virtual event is inspired by Vision Expo’s o
- Prevent Blindness to Kick Off Virtual Persons of Vision Award Event Honoring VSP Globalhttps://modernod.com/news/prevent-blindness-to-kick-off-virtual-persons-of-vision-award-event-honoring-vsp-global/2478212/Prevent Blindness announced that the 2020 Persons of Vision Award ceremony, honoring VSP Global, will be held through a series of virtual celebrations in September. The Prevent Blindness Persons of Vision Award recognizes an individual, corporation and/or organization whose inspired outloo
- Zeiss Adds Central Topography Feature to IOLMaster 700https://modernod.com/news/zeiss-adds-central-topography-feature-to-iol-master-700/2478210/Zeiss announced new software for the IOLMaster 700, including a new Central Topography feature. Zeiss says the software allows for more insights on corneal shape, empowers physicians to access surgical planning data o
- Seva Foundation Partners With IrisVision to Democratize Vision Care Through Innovationhttps://modernod.com/news/seva-foundation-partners-with-irisvision-to-democratize-vision-care-through-innovation/2478208/IrisVision announced it has partnered with the Seva Foundation to develop new technology that aims to democratize vision healthcare around the world. In the first phase of this unique public-private partnership, Seva, a global non-profit organization that provides eye
- PDL BioPharma Files With SEC For Potential Spin-Off of Lensarhttps://modernod.com/news/pdl-biopharma-announces-filing-of-a-form-10-registration-statement-with-the-sec-for-a-potential-spin-off-of-lensar-to-pdls-stockholders/2478207/PDL BioPharma announced that its majority owned medical device subsidiary, Lensar, has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) relating to a potential spin-off of Lensar from PDL. “Preparations for a spin-off of Lensar to PDL’